Clinical Trials Logo

Dilation clinical trials

View clinical trials related to Dilation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05274321 Completed - Dilation Clinical Trials

Efficacy of the Nanodropper Device on Pupillary Dilation

Start date: July 29, 2021
Phase: N/A
Study type: Interventional

Prescription eye drop bottles elute drops that exceed the capacity of the human eye by five times. This study describes performing in clinic dilation using a novel solution for combating medical waste with Nanodropper, an eye drop bottle adapter that creates smaller eye drops.

NCT ID: NCT05223478 Completed - Mydriasis Clinical Trials

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

MIRA-4
Start date: December 17, 2021
Phase: Phase 3
Study type: Interventional

The objectives of this study are: - To evaluate the safety of Nyxol in pediatric subjects - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically induced mydriasis in pediatric subjects The Sponsor intends to use this study to evaluate Nyxol in pediatric subjects aged 3 to 11 for the indication "the treatment of pharmacologically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents, or a combination thereof."

NCT ID: NCT05134974 Completed - Mydriasis Clinical Trials

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

MIRA-3
Start date: November 18, 2021
Phase: Phase 3
Study type: Interventional

The objectives of this study are: - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine - To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) - To evaluate the safety of Nyxol - To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis - To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling

NCT ID: NCT04620213 Completed - Mydriasis Clinical Trials

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Start date: November 18, 2020
Phase: Phase 3
Study type: Interventional

The objectives of this study are: - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine - To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) - To evaluate the safety of Nyxol - To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis

NCT ID: NCT04024891 Completed - Mydriasis Clinical Trials

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Start date: August 13, 2019
Phase: Phase 2
Study type: Interventional

The objectives of this study are: - To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis - To evaluate the safety of Nyxol - To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol